Seres Therapeutics (MCRB) Price to Book (2015 - 2026)

Seres Therapeutics has disclosed Price to Book across 12 years of filings, most recently posting 2.25 for Q2 2026.

• In Q2 2026, Price to Book fell 23.93% year-over-year to 2.25; the TTM figure through Jun 2026 stood at 2.25 (down 23.93% YoY), while the FY2025 annual figure was 3.22, down 69.17% from the prior year.
• Price to Book came in at 2.25 for Q2 2026 at Seres Therapeutics, down from 3.21 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 65.03 in Q4 2022 to a low of 20.24 in Q3 2023.
• Average Price to Book over 5 years is 6.57, with a median of 3.21 recorded in 2025.
• Year-over-year, Price to Book jumped 1017.3% in 2022 and slumped 284.89% in 2023.
• Over 5 years, Price to Book stood at 65.03 in 2022, then sank by 106.48% to 4.21 in 2023, then jumped by 347.47% to 10.43 in 2024, then tumbled by 69.17% to 3.22 in 2025, then tumbled by 30.18% to 2.25 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 2.25 in Q2 2026, 3.21 in Q1 2026, and 3.22 in Q4 2025.